Braidwell LP Grows Stock Holdings in Krystal Biotech, Inc. $KRYS

Key Points

• Braidwell LP significantly increased its stake in Krystal Biotech by 99.9%, acquiring an additional 200,244 shares, bringing its total to 400,744 shares, valued at approximately $72.25 million.
• Analysts generally maintain a positive outlook for Krystal Biotech, with a consensus rating of "Moderate Buy" and a target price averaging $210.38, despite some decreases in individual price targets.
• Krystal Biotech reported a Q2 EPS of $1.29, exceeding analyst expectations of $1.08, with a revenue of $96.04 million, indicating strong financial performance.

Braidwell LP boosted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 99.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 400,744 shares of the company's stock after acquiring an additional 200,244 shares during the period. Krystal Biotech comprises 2.5% of Braidwell LP's portfolio, making the stock its 14th largest holding. Braidwell LP owned approximately 1.39% of Krystal Biotech worth $72,254,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in KRYS. Hsbc Holdings PLC raised its position in Krystal Biotech by 195.2% during the fourth quarter. Hsbc Holdings PLC now owns 4,519 shares of the company's stock worth $718,000 after acquiring an additional 2,988 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Krystal Biotech by 12.7% during the fourth quarter. The Manufacturers Life Insurance Company now owns 35,206 shares of the company's stock worth $5,515,000 after acquiring an additional 3,981 shares during the last quarter. Northern Trust Corp raised its position in Krystal Biotech by 9.9% during the fourth quarter. Northern Trust Corp now owns 262,263 shares of the company's stock worth $41,086,000 after acquiring an additional 23,572 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its position in Krystal Biotech by 17.9% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 7,604 shares of the company's stock worth $1,191,000 after acquiring an additional 1,153 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in Krystal Biotech by 26.4% during the fourth quarter. Ameriprise Financial Inc. now owns 113,476 shares of the company's stock worth $17,779,000 after acquiring an additional 23,727 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 1,389 shares of the business's stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total value of $208,350.00. Following the completion of the sale, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. The trade was a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 49,800 shares of company stock valued at $7,487,943 in the last ninety days. 13.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on KRYS shares. Chardan Capital cut their target price on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research report on Friday, August 22nd. Citigroup reissued a "neutral" rating and issued a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. HC Wainwright reissued a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research report on Friday, August 22nd. Finally, Bank of America cut their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $210.38.

Krystal Biotech Stock Up 0.3%

Shares of NASDAQ:KRYS traded up $0.52 during trading on Friday, reaching $150.27. The stock had a trading volume of 308,397 shares, compared to its average volume of 327,403. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $207.84. The business has a fifty day moving average price of $146.42 and a 200-day moving average price of $154.19. The stock has a market cap of $4.35 billion, a P/E ratio of 30.54 and a beta of 0.66.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).